Navigation Links
Reportlinker Adds Targeted Therapeutics- Advancement in Gene Therapy and Stem Cell Therapy will Drive the Market

NEW YORK, Feb. 17, 2011 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Targeted Therapeutics- Advancement in Gene Therapy and Stem Cell Therapy will Drive the Market

Targeted Therapeutics- Advancement in Gene Therapy and Stem Cell Therapy will Drive the Market


GBI Research, the leading business intelligence provider, has released its latest research "Targeted Therapeutics- Advancement in Gene Therapy and Stem Cell Therapy will Drive the Market". The report provides in-depth analysis of the major targeted therapeutics. The Market Drivers and Restraints for all the types of Targeted Therapeutics (TT) are analyzed. The report provides comprehensive assessment of key pipeline therapies in the TT segment. The profiles of key promising molecules in the pipeline are mentioned. The regulatory Landscape is analyzed with focus on European and the US scenario. The regulatory landscape details about the major agencies for gene and stem cell therapies. The report profiles all the key companies dealing in TT with main focus on their deals involving M&A and licensing deals.

GBI Research finds that TT is the need of the hour for biotech and pharmaceutical companies to recover from the loss of revenue by patent expiry of conventional blockbuster drugs. Thus key pipeline molecules and key deals will help the companies to make a better future strategy.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

The report gives insight about the key deals which have taken place between biopharmaceutical companies and their influence. Reasons for considering strategic consolidation as the main objective of the companies have been mentioned. The major types of TT include small molecule drugs, protein/peptide therapeutics, monoclonal antibody therapeutics, RNA interference, gene therapy and stem cell therapy. The market drivers and restraints for these six classes are mentioned. From a commercial perspective there is a huge unmet medical need in difficult to treat diseases like cancer and autoimmune diseases. The unmet need is due to the lack of effective and efficacious therapies based on conventional mode of research. TT has the potential to satisfy this unmet need by being more efficacious, effective and safe. The strategic M&A deals and licensing deals of key companies such as Eli Lilly, Forest Laboratories, Hoffmann La-Roche, Isis Pharmaceuticals, J&J, Pfizer , Biogen, Antisoma and others are analyzed.


The scope of this report includes -

- Description of major types of TT with key market drivers and restraints.

- Analysis of the leading pipeline therapies which will define the future of TT market.

- Factors driving small molecule drugs, peptide/protein drugs, MAbs, RNA interference therapeutics, gene and stem cell therapy are analyzed.

- Key Regulatory Landscape is detailed for understanding the approval procedure of TT with main focus on gene and stem cell therapy.

- Major companies dealing in TT are profiled and their M&A and Licensing deals are mentioned.

- Key companies studied in this report are Eli Lilly, Pfizer, J&J, Hoffmann La- Roche, Biogen, Isis Pharmaceuticals and Antisoma.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Identify the advantages of TT and understand the potential that it can capture.

- Align your product portfolio to the TT market segment with high growth potential.

- Develop market-entry and market expansion strategies by identifying the leading TT segments poised for strong growth.

- Understand the key risks and issues which TT is facing and key solutions in development to address these issues.

- Develop key strategic initiatives by understanding the key focus areas with respect to pipeline portfolio of leading companies.

- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps and lead to revenue generation.

- Identify key players best positioned to take advantage of TT market potential.

To order this report:

: Targeted Therapeutics- Advancement in Gene Therapy and Stem Cell Therapy will Drive the Market

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg



US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Reportlinker Adds Frontiers in Carbohydrates Developments: Report 4; Research, Technologies; Biotechnology, Bioprocessing & Bioplastics - Food & Industrial Raw Material, January 2011
2. Reportlinker Adds Pipeline Insight: Cancer Overview- Breast and Gynecological Cancers - Promising agents emerge for BRCA positive patients
3. Reportlinker Adds Strategic Analysis of European Human Machine Interface (HMI) Market
4. Reportlinker Adds Amphotericin B - Comprehensive patent search
5. Reportlinker Adds Therapeutic Proteins to 2014
6. Reportlinker Adds Biochips - Products, Applications, Technologies and End-Use Markets Growth Analysis, 2009-2015
7. Reportlinker Adds Cell Therapy - Technologies, Markets and Companies
8. Reportlinker Adds The 2011 Molecular Diagnostics Market: DNA Probes and Biochips -- New Product Development Opportunities and Business Expansion Strategies for Instrument and Reagent Suppliers
9. Reportlinker Adds The 2011 Immunoprotein Diagnostics Market: US, Europe, Japan Test Volume and Sales Forecasts by Country and Market Segment
10. Reportlinker Adds The 2011 Clinical Chemistry and Immunodiagnostics Markets: US, Europe, Japan Product Development Opportunities and Business Expansion Strategies for Instrumentand Reagent Suppliers
11. Reportlinker Adds Biologic Therapeutic Drugs: Technologies and Global Markets
Post Your Comments:
(Date:11/25/2015)... November 25, 2015 Studies reveal ... human plaque and pave the way for more effective treatment ... cats     --> ... diagnosed health problems in cats, yet relatively little was understood ... collaborative studies have been conducted by researchers from the WALTHAM ...
(Date:11/25/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: ... prospects remain fundamentally strong and highlights the following ... received DSMB recommendation to continue the ZoptEC Phase ... the final interim efficacy and safety data ... men with heavily pretreated castration- and Taxane-resistant prostate ...
(Date:11/25/2015)... The Global Genomics Industry ... and in-depth study on the current state of ... ) , The report provides ... classifications, applications and industry chain structure. The Genomics ... including development trends, competitive landscape analysis, and key ...
(Date:11/24/2015)... N.J. (PRWEB) , ... November 24, 2015 , ... The ... the recipient of the 2016 USGA Green Section Award. Presented annually since 1961, the ... through his or her work with turfgrass. , Clarke, of Iselin, N.J., ...
Breaking Biology Technology:
(Date:10/29/2015)... 29, 2015 Daon, a global leader in ... released a new version of its IdentityX Platform ... North America have already installed IdentityX v4.0 ... a FIDO UAF certified server component as ... activate FIDO features. These customers include some of the ...
(Date:10/29/2015)... , Oct. 29, 2015  Connected health pioneer, ... the explosion of technology-enabled health and wellness, and the ... book, The Internet of Healthy Things ... or smartphones even existed, Dr. Kvedar, vice president, Connected ... health care delivery, moving care from the hospital or ...
(Date:10/29/2015)... , Oct. 29, 2015 Today, ... a partnership with 2XU, a global leader in ... a smart hat with advanced bio-sensing technology. The ... athletes to monitor key biometrics to improve overall ... partnership, the two companies will bring together the most ...
Breaking Biology News(10 mins):